Oculis (OCS) Competitors $17.40 +0.18 (+1.05%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$17.43 +0.04 (+0.20%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. BHC, NAMS, HCM, GMTX, IMVT, CPRX, KNSA, TARS, OGN, and ALVOShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Bausch Health Cos (BHC), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), Gemini Therapeutics (GMTX), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Bausch Health Cos NewAmsterdam Pharma HUTCHMED Gemini Therapeutics Immunovant Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Tarsus Pharmaceuticals Organon & Co. Alvotech Bausch Health Cos (NYSE:BHC) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Which has more volatility & risk, BHC or OCS? Bausch Health Cos has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Does the media prefer BHC or OCS? In the previous week, Bausch Health Cos had 1 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Bausch Health Cos and 4 mentions for Oculis. Oculis' average media sentiment score of 0.94 beat Bausch Health Cos' score of 0.82 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in BHC or OCS? 78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 20.0% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is BHC or OCS more profitable? Bausch Health Cos has a net margin of 0.99% compared to Oculis' net margin of -13,958.12%. Oculis' return on equity of -90.31% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Cos0.99% -852.36% 5.25% Oculis -13,958.12%-90.31%-67.85% Do analysts prefer BHC or OCS? Bausch Health Cos presently has a consensus target price of $9.00, suggesting a potential upside of 23.80%. Oculis has a consensus target price of $35.75, suggesting a potential upside of 105.46%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, BHC or OCS? Bausch Health Cos has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Cos$9.86B0.27-$46M$0.2627.96Oculis$780K973.95-$97.43M-$2.67-6.52 SummaryBausch Health Cos beats Oculis on 10 of the 16 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$751.87M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-6.5221.4375.2025.97Price / Sales973.95430.69514.97181.13Price / CashN/A46.6837.5660.44Price / Book9.119.6112.156.29Net Income-$97.43M-$53.29M$3.29B$270.96M7 Day Performance1.05%0.13%0.75%3.87%1 Month Performance-3.36%5.61%4.82%4.88%1 Year Performance45.61%10.49%60.59%26.12% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis3.1383 of 5 stars$17.40+1.0%$35.75+105.5%+45.6%$751.87M$780K-6.522Analyst UpgradeShort Interest ↓BHCBausch Health Cos4.5912 of 5 stars$7.41+3.6%$9.00+21.5%+15.4%$2.75B$9.63B28.5020,700NAMSNewAmsterdam Pharma3.5081 of 5 stars$24.05+0.4%$41.55+72.7%+51.2%$2.71B$45.56M-14.854News CoveragePositive NewsInsider TradeHCMHUTCHMED2.6528 of 5 stars$15.01+1.2%$28.00+86.5%+7.5%$2.62B$630.20M0.001,811News CoverageAnalyst DowngradeGap UpGMTXGemini TherapeuticsN/A$59.650.0%N/A+24.3%$2.58BN/A-59.6530IMVTImmunovant2.4725 of 5 stars$14.69-0.9%$35.20+139.6%-44.0%$2.56BN/A-5.15120Positive NewsCPRXCatalyst Pharmaceuticals4.945 of 5 stars$20.59+1.0%$33.20+61.2%-1.6%$2.52B$491.73M12.4880News CoveragePositive NewsAnalyst DowngradeInsider TradeKNSAKiniksa Pharmaceuticals International2.1575 of 5 stars$33.490.0%$41.17+22.9%+51.5%$2.48B$423.24M837.46220Short Interest ↑TARSTarsus Pharmaceuticals2.5745 of 5 stars$58.58+0.7%$66.67+13.8%+55.7%$2.47B$182.95M-25.1450Positive NewsInsider TradeOGNOrganon & Co.4.5243 of 5 stars$9.40+2.3%$18.00+91.6%-47.5%$2.45B$6.40B3.494,000News CoveragePositive NewsALVOAlvotech3.2521 of 5 stars$8.07+0.2%$14.00+73.5%-25.6%$2.43B$491.98M35.091,032Positive NewsShort Interest ↓ Related Companies and Tools Related Companies BHC Competitors NAMS Competitors HCM Competitors GMTX Competitors IMVT Competitors CPRX Competitors KNSA Competitors TARS Competitors OGN Competitors ALVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts